Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
J Chin Med Assoc. 2011 Dec;74(12):574-8. doi: 10.1016/j.jcma.2011.08.007. Epub 2011 Nov 21.
Massive premacular hemorrhage can cause sudden visual loss. We sought to evaluate the efficacy, safety and visual outcome of nonvitrectomizing vitreous surgery with intravitreal tissue plasminogen activator (t-pa) for long-lasting thick premacular hemorrhage. This retrospective, interventional study examined three consecutive eyes of three patients who received nonvitrectomizing vitreous surgery with intravitreal t-pa for the treatment of non-recent massive premacular hemorrhage. Detailed ophthalmoscopic examinations were performed pre- and postoperatively to evaluate the visual outcome, the resolution of premacular hemorrhage and the changes in lenticular opacity.In all three eyes, the premacular hemorrhage cleared after the procedure. Final best-corrected visual acuities improved from 6/30 to 6/10 in patient 1, 2/60 to 6/4 in patient 2, and 3/60 to 6/6 in patient 3. Operated and fellow eyes did not differ in terms of nuclear sclerosis. No complications from the procedure were noted.In these selected cases, nonvitrectomizing vitreous surgery with intravitreal t-pa was an effective and safe alternative treatment for non-recent massive premacular hemorrhage.
巨大的黄斑前出血可导致突发性视力丧失。我们旨在评估眼内注射组织型纤溶酶原激活物(t-PA)玻璃体切除术治疗长期弥漫性黄斑前出血的疗效、安全性和视力结果。这项回顾性、干预性研究纳入了 3 例患者的 3 只眼,他们因非近期的大量黄斑前出血接受眼内注射 t-PA 的非玻璃体切除术玻璃体手术治疗。术前和术后均进行详细的眼底检查,以评估视力结果、黄斑前出血的消退情况和晶状体混浊的变化。3 只眼中的黄斑前出血均在手术后清除。第 1 例患者的最终最佳矫正视力从 6/30 提高到 6/10,第 2 例患者从 2/60 提高到 6/4,第 3 例患者从 3/60 提高到 6/6。手术眼和对侧眼的核性硬化程度没有差异。未观察到手术相关并发症。在这些选定的病例中,眼内注射 t-PA 的非玻璃体切除术玻璃体手术是治疗非近期大量黄斑前出血的一种有效且安全的替代治疗方法。